Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004422|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : March 25, 2015
Assess the efficacy of a single infusion of a high titer pertussis immune globulin for the treatment of severe pertussis in children.
|Condition or disease||Intervention/treatment||Phase|
|Pertussis Whooping Cough||Drug: immune globulin||Phase 3|
PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive an infusion of either pertussis immune globulin or placebo (0.9% saline).
Patients are followed every 2 weeks for up to 6 months.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||174 participants|
|Study Start Date :||August 1997|
|Estimated Study Completion Date :||September 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004422
|Study Chair:||Scott A. Halperin||IWK Health Centre|